ACXPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (22 5月 2024 @ 00:12):

Stats
本日の出来高	2 978.00
平均出来高	75 472.00
時価総額	35.17M
EPS	$-282.95 ( 2024-05-15 )
次の収益日	( $-0.280 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.900
ATR14	$0.0130 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.59
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

ボリューム相関

長: -0.16 (neutral)

短: -0.11 (neutral)

Signal:(46.847) Neutral

Acurx Pharmaceuticals, 相関

10 最も正の相関
BNRG	0.947
QNRX	0.945
RMCF	0.944
AGFY	0.94
ACAD	0.94
FLGT	0.939
FWRD	0.938
SINT	0.937
AMPH	0.935
GOVX	0.931

10 最も負の相関
KINS	-0.953
GHRS	-0.943
TAYD	-0.932
ESTA	-0.931
CHW	-0.928
MMYT	-0.928
AMZN	-0.928
CRBP	-0.926
ALLT	-0.924
ROAD	-0.923

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Acurx Pharmaceuticals, 相関 - 通貨/商品

0.19
( neutral )

0.00
( neutral )

0.12
( neutral )

0.53
( weak )

-0.24
( neutral )

Acurx Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.